SCHEMBL5158701

SCHEMBL5158701

CCNc1nc(OCCc2ccccc2)nc2c1nc(Br)n2-c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 6/20 0.42
ADORA1 P30542 6/20 0.42
TMIGD3 P0DMS9 5/20 0.42
ADORA2A P29274 5/20 0.42
TLR7 Q9NYK1 1/20 0.40
CYP2C9 P11712 4/20 0.39
TSHR P16473 4/20 0.39
CYP2C19 P33261 4/20 0.39
ALDH1A1 P00352 3/20 0.39
CYP1A2 P05177 3/20 0.39
CYP3A4 P08684 3/20 0.39
CYP2D6 P10635 3/20 0.39
USP2 O75604 2/20 0.39
CASP1 P29466 2/20 0.39
CASP7 P55210 2/20 0.39
HSD17B10 Q99714 2/20 0.39
MEN1 O00255 1/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
BRCA1 P38398 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5163187 0.95 TMIGD3 (0.45) ADORA2BADORA1TMIGD3ADORA2ATLR7
SCHEMBL5161171 0.92 CYP1A2 (0.46) ADORA2BADORA1TMIGD3ADORA2ATLR7
SCHEMBL5162245 0.87 CYP1A2 (0.45) ADORA2BADORA1TMIGD3ADORA2ATLR7
SCHEMBL5161080 0.81 ADORA1 (0.48) ADORA2BADORA1TMIGD3ADORA2ATSHR
SCHEMBL5160526 0.81 ADORA2A (0.53) ADORA2BADORA1TMIGD3ADORA2ACYP2C9
SCHEMBL5161412 0.80 ADORA2A (0.41) ADORA2BADORA1TMIGD3ADORA2ACYP2C9
SCHEMBL5162993 0.79 TMIGD3 (0.54) ADORA2BADORA1TMIGD3ADORA2ACYP2C9
SCHEMBL5162193 0.77 TMIGD3 (0.42) ADORA2BADORA1TMIGD3ADORA2ACYP2C9
SCHEMBL5158790 0.77 ADORA1 (0.50) ADORA2BADORA1TMIGD3ADORA2AALDH1A1
SCHEMBL5359337 0.75 ADORA2A (0.46) ADORA2BADORA1TMIGD3ADORA2ATLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7189730-B2 A2A adenosine receptor antagonists CV THERAPEUTICS, INC. (US) 2007-03-13 US disclosed
EP-1456209-B1 A2A ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS INC (US) 2007-02-28 EP disclosed
US-20030149060-A1 A2A adenosine receptor antagonists CV THERAPEUTICS, INC. 2003-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149060-A1 A2A adenosine receptor antagonists ADORA2A, ADORA2B, ADORA3 ADORA2B 2/4885ADORA1 4/4885TMIGD3 1730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.